The Fifth Peoples Hospital Of Wuxi

Wuxi, China

The Fifth Peoples Hospital Of Wuxi

Wuxi, China

Time filter

Source Type

Huang L.-H.,The Fifth Peoples Hospital of Wuxi | Qiu Y.-W.,The Fifth Peoples Hospital of Wuxi | Hua H.-Y.,Jiangsu Institute for Prevention and Treatment of Parasitic Diseases | Niu X.-H.,The Third Peoples Hospital of Kunshan | And 6 more authors.
International Journal of Infectious Diseases | Year: 2013

Objective: To evaluate the efficacy and safety of entecavir (ETV) in patients with advanced schistosomiasis and hepatitis B virus (HBV) co-infection. Methods: Sixty-seven patients with advanced schistosomiasis and HBV co-infection were enrolled in this study. The patients were randomly divided into the ETV treatment group (n = 35) and the control group (n = 32). The patients in the control group adopted routine supportive therapy for 52 weeks, and those in the ETV treatment group received ETV at a dose of 0.5 mg once daily on the basis of routine supportive therapy for 52 weeks. Hepatic fibrosis markers (hyaluronic acid, type III procollagen, type IV collagen, laminin, and fibronectin), Ishak fibrosis score, alanine transaminase (ALT), HBV DNA, and Child-Pugh score were compared between the two groups. The intention to treat (ITT) population was used for the analysis. The measurement data and count data were analyzed by t-test and Chi-square test, respectively. Results: After 52 weeks of treatment, the hepatic fibrosis markers (hyaluronic acid, type III procollagen, type IV collagen, laminin, and fibronectin) were significantly improved in the ETV treatment group compared to the control group (all p < 0.05). A ≥1-point improvement in the Ishak fibrosis score was found in 25.7% (9/35) of the ETV group, and the mean change from the baseline in the Ishak fibrosis score was a 0.3-point reduction. The control group showed disease progression in the Ishak fibrosis score. More patients in the ETV group than in the control group had undetectable serum HBV DNA levels (82.9% vs. 3.1%, p < 0.05) and ALT normalization (68.6% vs. 18.3%, p < 0.05). The ETV treatment group demonstrated an improvement in Child-Pugh score at week 52 (-3.7 vs. 0.3, p < 0.05). In addition, no obvious adverse reactions were observed during ETV treatment. Conclusion: ETV is safe and effective in patients with advanced schistosomiasis and HBV co-infection. © 2013 International Society for Infectious Diseases.


Lin F.-S.,Nanjing Chest Hospital | Wu M.-Y.,The Fifth Peoples Hospital of Suzhou | Tu W.-J.,The Third Peoples Hospital of Changzhou | Pan H.-Q.,The Third Peoples Hospital of Zhenjiang | And 9 more authors.
Journal of Thoracic Disease | Year: 2015

Background: To investigate the prevalence of and risk factors for leukopenia in tuberculosis patients and the impact of anti-tuberculosis regimens on the occurrence of leukopenia in newly treated tuberculosis patients. Methods: A total of 1,904 tuberculosis patients were included in the study. A cross-sectional survey of the prevalence of leukopenia was initially conducted, and then factors influencing leukopenia were identified using Logistic regression analysis. Non-treatment factors influencing peripheral blood leukocyte counts were analyzed using univariate COX proportional hazards models. Covariate analysis was used to assess the independent effect of different anti-tuberculosis regimens on peripheral blood leukocyte counts. Results: Being female, advanced age and longer duration of previous anti-tuberculosis treatment (>6 month) were risk factors for leukopenia in tuberculosis patients, while secondary pulmonary tuberculosis, higher body mass index (BMI: 24-27.9 kg/m2), and higher degree of education (senior high school or above) were protective factors. Gender, vegetable consumption, drinking, pulmonary infection, other chronic diseases, and use of antibiotics were significantly associated with the development of leukopenia in patients on antituberculosis treatment. In tuberculosis patients treated with anti-tuberculosis regimens not containing antibiotics, peripheral blood leukocyte levels gradually declined with the prolongation of treatment duration. In tuberculosis patients treated with anti-tuberculosis regimens containing antibiotics, peripheral blood leukocyte levels showed a declining trend. Conclusions: Female patients, patients at advanced age and recurrent tuberculosis patients having longer previous anti-tuberculosis treatment are high-risk populations for leukopenia. Attention should be paid to the influence of vegetable consumption and drinking, co-morbidities and use of antibiotics during antituberculosis treatment. © Journal of Thoracic Disease.


Chen J.,The Fifth Peoples Hospital Of Wuxi | Wang X.-G.,The Fifth Peoples Hospital Of Wuxi | Huang L.-H.,The Fifth Peoples Hospital Of Wuxi
World Chinese Journal of Digestology | Year: 2016

AIM: To evaluate the therapeutic effect of Shugan Yipi capsules on hypersplenism in patients with hepatitis B cirrhosis. METHODS: Sixty patients with early hepatitis B were randomly divided into a Shugan Yipi capsules group (observation group) and a silybin meglumine group (control group). After 3 mo of treatment, clinical manifestations, liver function, blood tests, splenic vein trunk width change, spleen diameter change, portal vein blood flow change, liver ultrasonic images and FibroTouch change were compared between the two groups. RESULTS: There were no significant differences in reduced transaminase indicators and liver fibrosis between the two groups (P > 0.05). The reduction in jaundice index in the treatment group was better than that in the control group. The improvement of the spleen retraction was also significantly different between the two groups (P < 0.05, 0.01). CONCLUSION: Shugan Yipi capsules can improve hypersplenism in patients with hepatitis B cirrhosis. © 2016 Baishideng Publishing Group Inc. All rights reserved.


Wang X.-G.,The Fifth Peoples Hospital Of Wuxi | Huang L.-H.,The Fifth Peoples Hospital Of Wuxi
World Chinese Journal of Digestology | Year: 2016

AIM: To observe the therapeutic effect of fasted exercise on nonalcoholic fatty hepatitis. METHODS: one hundr ed and twenty nonalcoholic fatty liver patients were randomly divided into a preprandial exercise group, a postprandial exercise group and a no exercise (control) group, with 40 cases in each group. The exercise was outdoor running at 4 km/h. All of the patients had a daily intake of total calories less than 2092 kJ (500 kcal). Detection of alanine aminotransferase (ALT) and gamma glutamyl transpeptidase (γ-GT) and calculation of body mass index and liver fat content were performed once a month for 6 mo. ALT and γ-GT were measured with an Au5400 automatic biochemistry analyzer. Fibroscantouch was used to determine liver fat content. RESULTS: Body mass index in the control group had no obvious decline. Compared with the control group, body mass index was slowly decreased in the postprandial exercise group, and a significant difference was observed from 8 wk (P < 0.05). Body mass index in the preprandial exercise group decreased significantly, and a significant difference was observed at 4 wk (P < 0.01). At 8 wk, body mass index in the preprandial exercise group reached a normal level (23.4 kg/m2 ± 3.0 kg/m2). Both kinds of exercise had a curative effect on the recovery of ALT, which was more apparent in the preprandial exercise group. ALT at 8 wk in the preprandial exercise group returned to the normal level (50.3 U/L ± 7.6 U/L). In the control group and postprandial exercise group ALT declined slightly, and failed to return the normal level at 24 wk. The level of γ-GT in each group slowly declined and returned to the normal level at 24 wk, showing no difference between groups at corresponding time points (P > 0.05). The fat in the liver was significantly reduced in the two exercise groups, which was faster in the preprandial exercise group. The intrahepatic fat in the preprandial exercise group at 4 wk (246.4 db/m ± 27.8 db/m) was significantly reduced compared with the control group (P < 0.01), while the postprandial exercise group showed a significant difference (P < 0.05) at 20 wk (250.1 db/m ± 13.0 db/m). CONCLUSION: Fasted exercise is superior to postprandial exercise in terms of nonalcoholic fatty liver inflammation and weight control. © 2016 Baishideng Publishing Group Inc. All rights reserved.


Zhang B.,The Fifth Peoples Hospital of Wuxi | Hu M.,The Fifth Peoples Hospital of Wuxi | Huang L.,The Fifth Peoples Hospital of Wuxi | Pu Y.,The Fifth Peoples Hospital of Wuxi | And 3 more authors.
Experimental and Therapeutic Medicine | Year: 2014

The aim of the present study was to observe the effects of Fuzheng Huayu capsule combined with Pegasys (peginterferon α-2a) on hepatic fibrosis in rats and in the treatment of patients with genotype 1 hepatitis C and hepatic cirrhosis. A dimethylnitrosamine (DMN)-induced rat model of liver injury was established. Fuzheng Huayu capsule combined with Pegasys was administered to the rats and the DMN-induced hepatocyte apoptosis was observed. In addition, a total of 100 patients with genotype 1 hepatitis C and hepatic cirrhosis were treated by oral administration of Fuzheng Huayu capsule combined with Pegasys or with Pegasys alone. The therapeutic effect of Fuzheng Huayu capsule combined with Pegasys was analyzed. Following the oral administration of Fuzheng Huayu capsule combined with Pegasys to the DMN model rats, the expression of α-smooth muscle actin was found to be significantly reduced, hemopoietic stem cell apoptosis was increased and liver cell apoptosis was reduced. These indices were significantly different compared with those in the model group (P<0.05). Liver function and liver fibrosis were markedly recovered in hepatitis C patients with hepatic cirrhosis following treatment with the combination treatment compared with those in the patients treated with Pegasys alone (P<0.05). In conclusion, the combination of Fuzheng Huayu capsule with Pegasys inhibited liver fibrosis and cell apoptosis, and may be a novel therapeutic strategy for the treatment of patients with compensated cirrhosis due to hepatitis C. This study provides a method for the optimization of existing treatment strategies and for the establishment of potentially effective combination therapies.


Kuai S.G.,The Fifth Peoples Hospital of Wuxi
Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] | Year: 2013

To assess the response in THP-1 treated with Rv3671c protein in Mycobacterium tuberculosis (M.tuberculosis). The gene encoding Rv3671c protein of M.tuberculosis was cloned into pET-28a vector and then expressed in Escherichia coli. The Rv3671c was purified with Ni-NTA affinity and ion exchange chromatography. The detection of protein concentration was by Lowry method.THP-1 cell was stimulated with Rv3671c protein and cells were analyzed by Hochest staining under fluorescence microscopy to assay cell death (apoptosis and necrosis). TNF-α and IL-1β were detected by ELISA at each stimulating time. The Rv3671c protein of M.tuberculosis was successfully expressed in Escherichia coli. The purity of recombinant Rv3671c protein was 95%, and the protein concentration was up to 0.4 mg/ml. The nucleus of THP-1 was isolated and necrosis-like under fluorescence when cells were stimulated by Rv3671c protein. The levels of TNF-α and IL-1β in supernatant were 19 000 and 16 500 pg/ml respectively, and were significantly higher than control cells with the levels of 2100 and 3800 pg/ml separately. The necrosis of THP-1 cells could be stimulated by Rv3671c protein of M.tuberculosis and it was probably associated with high cytokines TNF-α and IL-1β levels.


Wang J.-H.,The Fifth Peoples Hospital Of Wuxi | Hu M.-T.,The Fifth Peoples Hospital Of Wuxi | Wu H.-Y.,The Fifth Peoples Hospital Of Wuxi | Su T.-T.,The Fifth Peoples Hospital Of Wuxi | And 5 more authors.
World Chinese Journal of Digestology | Year: 2014

Aim: To assess the role of cellular immunity in the development of chronic hepatitis B.Methods: Patients with chronic hepatitis B were collected. Alanine aminotransferase (ALT) and viral load were detected. CD3+, CD4+, CD8+, CD4+/CD8+ ratio, Th1, Th2, Th1/Th2 ratio, Tc1, Th17, Tc17, Th17/Tc17 ratio, regulatory T cells (Treg), and Th17/Treg ratio were detected by flow cytometry (FCM). The correlations between the immune indicators and transaminase and viral load were evaluated.Results: Th17 percentage and Th17/Treg ratio were significantly higher in chronic hepatitis B patients with low viral load than in those with normal/high viral load (5.81% vs 2.51%, 2.23%; 23.54 vs 19.42, 9.85). Th2 percentage, Tc1 percentage, and Th17/Tc17 ratio were significantly higher in chronic hepatitis B patients with normal liver function than in those with mild/severe liver damage (6.75% vs 3.09%, 3.58%; 70.43% vs 36.97%, 35.86%; 71.18 vs 11.35, 12.58). Tc17 percentage was significantly lower in chronic hepatitis B patients with severe liver dysfunction than in those with mild liver dysfunction (0.42% vs 1.69%).Conclusion: Cellular immune status in patients with chronic hepatitis B has an impact on viral load and liver dysfunction level, in which Th17/Tc17 ratio may play an important role. © 2014 Baishideng Publishing Group Inc. All rights reserved.


PubMed | The Fifth Peoples Hospital of Wuxi
Type: Journal Article | Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | Year: 2013

To evaluate the efficacy and safety of entecavir (ETV) in patients with advanced schistosomiasis and hepatitis B virus (HBV) co-infection.Sixty-seven patients with advanced schistosomiasis and HBV co-infection were enrolled in this study. The patients were randomly divided into the ETV treatment group (n=35) and the control group (n=32). The patients in the control group adopted routine supportive therapy for 52 weeks, and those in the ETV treatment group received ETV at a dose of 0.5mg once daily on the basis of routine supportive therapy for 52 weeks. Hepatic fibrosis markers (hyaluronic acid, type III procollagen, type IV collagen, laminin, and fibronectin), Ishak fibrosis score, alanine transaminase (ALT), HBV DNA, and Child-Pugh score were compared between the two groups. The intention to treat (ITT) population was used for the analysis. The measurement data and count data were analyzed by t-test and Chi-square test, respectively.After 52 weeks of treatment, the hepatic fibrosis markers (hyaluronic acid, type III procollagen, type IV collagen, laminin, and fibronectin) were significantly improved in the ETV treatment group compared to the control group (all p<0.05). A 1-point improvement in the Ishak fibrosis score was found in 25.7% (9/35) of the ETV group, and the mean change from the baseline in the Ishak fibrosis score was a 0.3-point reduction. The control group showed disease progression in the Ishak fibrosis score. More patients in the ETV group than in the control group had undetectable serum HBV DNA levels (82.9% vs. 3.1%, p<0.05) and ALT normalization (68.6% vs. 18.3%, p<0.05). The ETV treatment group demonstrated an improvement in Child-Pugh score at week 52 (-3.7 vs. 0.3, p<0.05). In addition, no obvious adverse reactions were observed during ETV treatment.ETV is safe and effective in patients with advanced schistosomiasis and HBV co-infection.


PubMed | The Fifth Peoples Hospital of Wuxi
Type: Journal Article | Journal: Experimental and therapeutic medicine | Year: 2014

The aim of the present study was to observe the effects of Fuzheng Huayu capsule combined with Pegasys (peginterferon -2a) on hepatic fibrosis in rats and in the treatment of patients with genotype 1 hepatitis C and hepatic cirrhosis. A dimethylnitrosamine (DMN)-induced rat model of liver injury was established. Fuzheng Huayu capsule combined with Pegasys was administered to the rats and the DMN-induced hepatocyte apoptosis was observed. In addition, a total of 100 patients with genotype 1 hepatitis C and hepatic cirrhosis were treated by oral administration of Fuzheng Huayu capsule combined with Pegasys or with Pegasys alone. The therapeutic effect of Fuzheng Huayu capsule combined with Pegasys was analyzed. Following the oral administration of Fuzheng Huayu capsule combined with Pegasys to the DMN model rats, the expression of -smooth muscle actin was found to be significantly reduced, hemopoietic stem cell apoptosis was increased and liver cell apoptosis was reduced. These indices were significantly different compared with those in the model group (P<0.05). Liver function and liver fibrosis were markedly recovered in hepatitis C patients with hepatic cirrhosis following treatment with the combination treatment compared with those in the patients treated with Pegasys alone (P<0.05). In conclusion, the combination of Fuzheng Huayu capsule with Pegasys inhibited liver fibrosis and cell apoptosis, and may be a novel therapeutic strategy for the treatment of patients with compensated cirrhosis due to hepatitis C. This study provides a method for the optimization of existing treatment strategies and for the establishment of potentially effective combination therapies.

Loading The Fifth Peoples Hospital Of Wuxi collaborators
Loading The Fifth Peoples Hospital Of Wuxi collaborators